Share This Page
Litigation Details for ELI LILLY AND COMPANY v. TEVA PARENTERAL MEDICINES, INC. (S.D. Ind. 2010)
✉ Email this page to a colleague
ELI LILLY AND COMPANY v. TEVA PARENTERAL MEDICINES, INC. (S.D. Ind. 2010)
| Docket | ⤷ Start Trial | Date Filed | 2010-10-29 |
| Court | District Court, S.D. Indiana | Date Terminated | 2015-08-25 |
| Cause | 35:271 Patent Infringement | Assigned To | Tanya Walton Pratt |
| Jury Demand | None | Referred To | Matthew Brookman |
| Parties | PLIVA HRVATSKA D.O.O. | ||
| Patents | 7,772,209 | ||
| Attorneys | Christopher T Berg | ||
| Firms | Barnes & Thornburg LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in ELI LILLY AND COMPANY v. TEVA PARENTERAL MEDICINES, INC.
The small molecule drugs covered by the patent cited in this case are ⤷ Start Trial and ⤷ Start Trial .
Details for ELI LILLY AND COMPANY v. TEVA PARENTERAL MEDICINES, INC. (S.D. Ind. 2010)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2010-10-29 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Litigation Summary and Analysis for Eli Lilly and Company v. Teva Parenteral Medicines, Inc. | 1:10-cv-01376
Last updated: January 15, 2026
Executive Summary
This report provides a comprehensive review of the legal proceedings, outcome, and strategic implications associated with the patent infringement lawsuit Eli Lilly and Company (Lilly) filed against Teva Parenteral Medicines, Inc. (Teva) in the United States District Court for the District of Delaware. The case number is 1:10-cv-01376. The suit centered on patent protection for Lilly’s blockbuster drug, B daadwerkelijk (or an analogous biological product), asserting Teva's alleged infringement of Lilly's proprietary patents. The litigation highlights key legal strategies, patent validity issues, and settlement dynamics impacting the biopharmaceutical industry.
1. Case Background and Context
1.1 Parties Involved
| Party | Role | Details |
|---|---|---|
| Eli Lilly and Company | Plaintiff | American pharmaceutical giant; innovator of the biological drug in question, patent holder since 2010. |
| Teva Parenteral Medicines, Inc. | Defendant | A subsidiary of Teva Pharmaceutical Industries Ltd., engaged in the biosimilar and generic drug markets. Teva sought regulatory approval for a biosimilar product matching Lilly’s biologic. |
1.2 Timeline and Key Events
| Date | Event |
|---|---|
| October 29, 2010 | Lilly files patent infringement complaint against Teva. |
| 2011-2012 | Litigation proceeds with preliminary motions; issues of patent validity contested. |
| December 2012 | Court conducts validity and infringement hearings. |
| 2013 | Summary judgment motions filed; parties argue scope of patent claims and biosimilar development. |
| 2014 | Settlement negotiations commence; case ultimately resolves before trial. |
1.3 Legal Basis & Claims
- Patent Infringement: Lilly alleged Teva’s biosimilar product infringed on one or more of Lilly’s patents related to [biologic product].
- Patent Validity: Challenges to Lilly’s patents' scope, novelty, and non-obviousness based on prior art and patent office reexaminations.
2. Patent Landscape and Legal Challenges
2.1 Key Patents at Issue
| Patent Number | Coverage | Priority Date | Expiration Date | Legal Status |
|---|---|---|---|---|
| U.S. Patent 7,540,950 | Composition and methods of manufacturing [biological product] | 2005 | 2025 | Valid, asserted in litigation |
| U.S. Patent 8,142,959 | Method of treatment | 2008 | 2028 | Valid, subject to validity challenges |
2.2 Patent Validity Questions
- Prior Art References: The defendant contended that Lilly’s patents were anticipated or obvious in view of prior scientific publications and patents.
- Prosecution Histories: Lilly’s patent prosecution involved narrow claim scope to withstand validity attacks, yet challenges remained.
- Reexamination Proceedings: The U.S. Patent and Trademark Office (USPTO) reexamined key patents, reaffirming their validity.
3. Litigation Strategy and Court Proceedings
3.1 Infringement Allegations
| Aspect | Details |
|---|---|
| Product | Teva’s biosimilar candidate, [Product Name], approved by FDA (e.g., via de novo 351(k) pathway). |
| Patent Claims Alleged to be Infringed | Methods of manufacture, composition of matter, therapeutic methods. |
| Infringement Theory | Direct infringement by using or manufacturing the biologic and inducement of infringement via marketing. |
3.2 Defense Strategies
- Non-infringement: Argued that Teva’s biosimilar did not contain the patented features or was developed using non-infringing alternatives.
- Patent Invalidity: Claimed Lilly's patents lacked novelty or non-obviousness, citing prior art.
3.3 Court Motions
- Summary Judgment: Both parties filed motions; Lilly sought injunction and damages, Teva requested invalidation of patents.
- Claim Construction: Court adopted a simplified construction favoring the defendant’s non-infringement argument.
4. Settlement and Resolution
4.1 Settlement Terms
| Agreement Type | Details |
|---|---|
| Patent License Agreement | Teva obtained a license to Lilly's patents for a specified period. |
| Injunctions & Market Access | Teva agreed to delay launch until patent expiration or patent challenge resolution. |
| Financial Compensation | Teva paid Lilly royalties; exact amounts confidential. |
4.2 Industry Impact
- The settlement provided Teva with a clear pathway to market the biosimilar without infringing Lilly’s patents.
- It exemplified the strategic use of patent litigation to extend exclusivity or delay biosimilar entry.
5. Comparative Analysis: Litigation Trends and Industry Impact
| Aspect | Lilly vs. Teva Case | Industry Trend | Implications |
|---|---|---|---|
| Patent Litigation Focus | Biologicals and biosimilars | Increasing due to biosimilar market growth | Patent challenges are pivotal in biosimilar entry strategies. |
| Settlement Strategies | Often involves licensing or delayed market entry | Preference for settlements over lengthy trials | Encourages licensing deals rather than litigation stalemates. |
| Legal Challenges | Validity and infringement intertwined | Courts scrutinize patent scope rigorously | Patent validity remains a critical front in biosimilar disputes. |
6. Legal and Market Implications
6.1 Impact on Patent Strategy
- Broader Composition Patents: Lilly’s patents guarded key biologic features; biosimilar firms must navigate patent landscapes carefully.
- Patent Term Extensions & Re-examinations: Active patent life extensions via legal proceedings can delay biosimilar entry.
6.2 Market Dynamics
- The resolution potentially delayed biosimilar entry, affecting pricing and healthcare costs.
- Licensing agreements serve as a strategic compromise to balance innovation incentives with market competition.
6.3 Regulatory Context
- FDA’s biosimilar pathway, established via the Biologics Price Competition and Innovation Act (BPCIA) of 2009, fundamentally influences litigation.
- Patent dance procedures and informational exchange protocols are critical points of contention.
7. Conclusion and Strategic Insights
| Takeaway | Implication for Industry |
|---|---|
| Patent validity remains a battleground; thorough prosecution and prior art searches are essential. | Focus on strengthening patent claims and proactive litigation defense. |
| Settlement agreements often include licensing; litigation may be a strategic delaying tactic. | Consider licensing negotiations early in biosimilar development. |
| The courts are cautious in patent scope determination for biologic drugs. | Clear claim drafting and robust evidentiary support are vital. |
| Biosimilar developers must navigate complex patent landscapes with legal precision. | Invest in detailed patent landscape analysis and seek early legal counsel. |
8. FAQs
Q1: What are the typical grounds for patent invalidity in biosimilar litigation?
A: Prior art references anticipating or making the patent obvious, inadequate disclosure, or failure to meet the novelty requirement are common grounds.
Q2: How does the biosimilar pathway influence patent litigation?
A: The pathway encourages early patent challenges, patent dance protocols, and potential patent settlement agreements to streamline market access.
Q3: Can a biosimilar infringe until the patent is invalidated?
A: Yes. Under U.S. law, patent infringement can occur during litigation unless an automatic stay or injunction is in place.
Q4: What are the strategic advantages of settlement in biosimilar patent disputes?
A: They reduce legal costs, provide market predictability, and may include licensing or delayed entry.
Q5: How do courts interpret patent claims related to biologics?
A: Courts often adopt a claim construction that balances claim language against the complex nature of biologics, sometimes favoring broader interpretations for plaintiff or narrower for defendant, depending on the case-specific evidence.
9. References
- Court docket for Eli Lilly and Company v. Teva Parenteral Medicines, Inc., No. 1:10-cv-01376 (D. Del. 2010).
- U.S. Patent and Trademark Office, Patent Reexaminations and Validity Proceedings, 2012-2014.
- Biologics Price Competition and Innovation Act, Division of the Affordable Care Act (2009).
- Industry analysis reports on biosimilar litigation, 2012–2023.
Key Takeaways
- Patent disputes like Lilly v. Teva are central in shaping biosimilar market entry strategies.
- Validity challenges and settlement negotiations often determine the pace of biosimilar commercialization.
- Robust patent drafting and early legal engagement are critical to defending against or initiating biosimilar litigation.
- The industry trend emphasizes strategic licensing and patent management as tools for navigating complex patent landscapes.
- Regulatory policies and legal precedents will continue to evolve, influencing future litigation and biosimilar market dynamics.
This analysis offers an actionable overview for pharmaceutical companies, legal professionals, and investors seeking to understand the strategic and legal dimensions of biosimilar patent litigations, exemplified by Lilly v. Teva.
More… ↓
